KRYS – Krystal Biotech, Inc.
Krystal Biotech, Inc.KRYS
$183.02Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,297,144,320.00
EPSttm : 4.91
Krystal Biotech, Inc.
$183.02
1.36%$2.45Float Short %
14.5
Margin Of Safety %
-7
Put/Call OI Ratio
2.7
EPS Next Q Diff
-0.04
EPS Last/This Y
1.8
EPS This/Next Y
3.39
Price
183.23
Target Price
205.82
Analyst Recom
1.17
Performance Q
22.91
Relative Volume
0.59
Beta
0.64
Ticker: KRYS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | KRYS | 145.22 | 2.71 | 0.01 | 10269 |
| 2025-09-09 | KRYS | 140.91 | 2.62 | 0.13 | 10369 |
| 2025-09-10 | KRYS | 137.31 | 2.58 | 0.53 | 10410 |
| 2025-09-11 | KRYS | 144.18 | 2.48 | 0.02 | 10655 |
| 2025-09-12 | KRYS | 143.85 | 2.56 | 0.48 | 10571 |
| 2025-09-15 | KRYS | 155.99 | 2.53 | 0.33 | 10525 |
| 2025-09-16 | KRYS | 154.26 | 2.48 | 0.02 | 10634 |
| 2025-09-17 | KRYS | 154.05 | 2.4546341463415 | 0.58620689655172 | 10623 |
| 2025-09-18 | KRYS | 160.57 | 2.45 | 0.04 | 10627 |
| 2025-09-19 | KRYS | 163.9 | 2.33 | 0.06 | 10789 |
| 2025-09-22 | KRYS | 165.54 | 2.68 | 0.04 | 9643 |
| 2025-09-23 | KRYS | 165.09 | 2.64 | 0.15 | 9673 |
| 2025-09-24 | KRYS | 162.03 | 2.74 | 0.47 | 9928 |
| 2025-09-25 | KRYS | 161.15 | 2.73 | 0.01 | 9920 |
| 2025-09-26 | KRYS | 168.03 | 2.73 | 0.96 | 9928 |
| 2025-09-29 | KRYS | 176.88 | 2.72 | 0.71 | 9934 |
| 2025-09-30 | KRYS | 176.47 | 2.74 | 0.21 | 9976 |
| 2025-10-01 | KRYS | 179.49 | 2.71 | 0.60 | 10024 |
| 2025-10-02 | KRYS | 181.73 | 2.70 | 3.29 | 10049 |
| 2025-10-03 | KRYS | 183.57 | 2.71 | 0.23 | 10090 |
| 2025-10-06 | KRYS | 180.55 | 2.70 | 0.01 | 10099 |
| 2025-10-07 | KRYS | 183.23 | 2.70 | 0.04 | 10110 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | KRYS | 145.20 | -13.0 | 165.6 | 4.92 |
| 2025-09-09 | KRYS | 141.09 | -13.0 | 167.6 | 4.92 |
| 2025-09-10 | KRYS | 137.45 | -13.0 | 168.3 | 4.92 |
| 2025-09-11 | KRYS | 144.36 | -13.0 | 198.8 | 4.92 |
| 2025-09-12 | KRYS | 143.98 | -13.0 | 177.7 | 4.92 |
| 2025-09-15 | KRYS | 155.85 | -13.0 | 212.2 | 4.92 |
| 2025-09-16 | KRYS | 154.38 | -13.0 | 175.5 | 4.92 |
| 2025-09-17 | KRYS | 154.01 | -13.0 | 177.9 | 4.92 |
| 2025-09-18 | KRYS | 160.52 | -13.0 | 194.9 | 4.92 |
| 2025-09-19 | KRYS | 163.61 | -13.0 | 186.0 | 4.92 |
| 2025-09-22 | KRYS | 165.42 | -13.0 | 182.6 | 4.92 |
| 2025-09-23 | KRYS | 164.96 | -13.0 | 177.7 | 4.92 |
| 2025-09-24 | KRYS | 161.96 | -13.0 | 171.7 | 4.92 |
| 2025-09-25 | KRYS | 161.15 | -13.0 | 176.7 | 4.92 |
| 2025-09-26 | KRYS | 167.82 | -13.0 | 194.8 | 4.92 |
| 2025-09-29 | KRYS | 176.88 | -13.0 | 199.5 | 4.92 |
| 2025-09-30 | KRYS | 176.62 | -13.0 | 178.5 | 4.92 |
| 2025-10-01 | KRYS | 179.77 | -13.0 | 185.8 | 4.92 |
| 2025-10-02 | KRYS | 181.59 | -13.0 | 183.0 | 4.92 |
| 2025-10-03 | KRYS | 183.54 | -13.0 | 182.6 | 4.92 |
| 2025-10-06 | KRYS | 180.27 | -13.0 | 175.8 | 4.92 |
| 2025-10-07 | KRYS | 183.23 | -13.0 | 184.4 | 4.92 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | KRYS | -4.67 | 0.47 | 14.01 |
| 2025-09-09 | KRYS | -4.67 | 0.47 | 14.01 |
| 2025-09-10 | KRYS | -4.67 | 0.47 | 14.01 |
| 2025-09-11 | KRYS | -4.67 | 0.47 | 13.87 |
| 2025-09-12 | KRYS | -4.67 | 0.47 | 13.87 |
| 2025-09-15 | KRYS | -2.39 | 0.49 | 13.87 |
| 2025-09-16 | KRYS | -2.39 | 0.49 | 13.87 |
| 2025-09-17 | KRYS | -2.39 | 0.49 | 13.87 |
| 2025-09-18 | KRYS | -2.39 | 0.49 | 13.87 |
| 2025-09-19 | KRYS | -2.39 | 0.49 | 13.87 |
| 2025-09-22 | KRYS | -2.39 | 0.51 | 13.87 |
| 2025-09-23 | KRYS | -2.39 | 0.51 | 13.87 |
| 2025-09-24 | KRYS | -2.39 | 0.51 | 13.87 |
| 2025-09-25 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-09-26 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-09-29 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-09-30 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-10-01 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-10-02 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-10-03 | KRYS | -2.39 | 0.51 | 14.50 |
| 2025-10-06 | KRYS | -2.39 | 0.74 | 14.50 |
| 2025-10-07 | KRYS | -2.39 | 0.74 | 14.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.29
Avg. EPS Est. Current Quarter
1.12
Avg. EPS Est. Next Quarter
1.25
Insider Transactions
-2.39
Institutional Transactions
0.74
Beta
0.64
Average Sales Estimate Current Quarter
93
Average Sales Estimate Next Quarter
105
Fair Value
170.94
Quality Score
88
Growth Score
40
Sentiment Score
60
Actual DrawDown %
16.5
Max Drawdown 5-Year %
-53.4
Target Price
205.82
P/E
37.23
Forward P/E
23.33
PEG
0.65
P/S
14.75
P/B
5.09
P/Free Cash Flow
28.57
EPS
4.92
Average EPS Est. Cur. Y
4.92
EPS Next Y. (Est.)
8.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.85
Relative Volume
0.59
Return on Equity vs Sector %
-11.1
Return on Equity vs Industry %
2.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-1.19
EBIT Estimation
184.4
Krystal Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading